Dr. Peiffer is a co-founder and heads Lineagen's pediatric genetics efforts within Lineagen's Clinical Services Team, overseeing the company's expanding science portfolio and clinical intelligence work. A practicing physician with a current appointment in Pediatric Genetics at the University of Utah, as well as former investigator in the Department of Human Genetics at the University of Utah, Dr. Peiffer combines expertise in both the medical and scientific significance of clinical genetics.

Dr. Peiffer earned his Bachelor's degree in Physiology from McGill University, and his graduate/postgraduate degrees in Medicine, Pharmacology and Physiology from Laval University.

Rena Vanzo heads Lineagen's Genetic Counseling Team within the Clinical Services Team. She provides physicians and families with consultation, education, and support throughout the testing and evaluation process.
 

Ms. Vanzo was formerly a clinical pediatric and metabolic genetic counselor at the University of Utah's Department of Pediatrics. She received her Master of Science in Medical Genetics from Indiana University (2008) and her Bachelor of Science in Psychology from the University of Wisconsin (2004).

E. Robert Wassman, M.D. is Lineagen’s Chief Medical Adviser and joined Lineagen with more than 30 years of experience in genetics-based diagnostics. Prior to joining Lineagen, Dr. Wassman served in various positions focused on advancing the translation and delivery of cutting-edge diagnostic technology into clinical service, including Chief Medical Officer at Rosetta Genomics; Chief Medical and Chief Genomics Officer at Generation Health; SVP/CMO of Helicos BioSciences; Co-Founder and CMO of Good Start Genetics, and President/CMO of Celula, Inc. Prior to leading these start-up ventures, he was the Senior Medical Officer of Genzyme Genetics after helping lead Alfigen/The Genetics Institute for many years. In addition he has served as a consultant to numerous companies introducing other key innovations to the market.

Dr. Wassman received his B.S. from Yale University, and his M.D. from Albany Medical College. He took post-graduate training in Pediatrics and Medical Genetics at NY Hospital-Cornell University Medical Center and UCLA respectively, and is Board certified in these disciplines.

Dr. Paul is a co-founder and has served as Chief Executive Officer of Lineagen since its inception. Dr. Paul has been recognized as one of Utah’s leading venture entrepreneurs and was a Utah Governor’s Appointee to the Steering Committee for the Utah Technology Industry Commission. Prior to Lineagen, he was President and Chief Operating Officer of Lineagen Research Corporation, Vice President of Business Development at Huntsman Biotechnology Corporation and Director of Strategic Development at NPS Pharmaceuticals.

Dr. Paul has also worked at the University of Utah Technology Transfer Office where he participated in the marketing of University inventions to the pharmaceutical and biotechnology industries. Dr. Paul is a licensed patent agent of the United States Patent and Trademark Office. Dr. Paul earned his B.A. from Colby College and his Ph.D. in Molecular Biology and Biochemistry from the University of Utah.

David Kabakoff joined Sofinnova Ventures as an Executive Partner in 2007, and also serves as a partner in HealthQuest Capital. Dr. Kabakoff has more than 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical, diagnostics, and drug delivery fields. He served as Chairman of Trius Therapeutics (acquired by Cubist), Chairman of Amplimmune (acquired by Astra Zeneca), as a Director of InterMune, Inc. (acquired by Roche), and Director of Allylix, Inc. (acquired by Evolva). Dr. Kabakoff also served as a Board Observer at Intellikine (acquired by Takeda).  He currently serves as the Chairman of the Board of Lineagen and as an Observer to the Board of Castle BioSciences and of Histogenics.

Dr. Kabakoff co-founded Salmedix, Inc., a developer of cancer drugs, and served as Chairman and Chief Executive Officer (acquired by Cephalon Inc.).  Dr. Kabakoff also held the positions of Executive Vice President of Dura, a specialty respiratory pharmaceutical and pulmonary drug delivery company, and President and Chief Executive Officer of Spiros Development Corp. Prior to Dura, Dr. Kabakoff was Chief Executive Officer of Corvas International and held senior executive positions with Hybritech, Inc.

Dr. Kabakoff received his Ph.D. from Yale University and his B.A. from Case Western Reserve University.

A founding member of Lineagen Research Corporation as well as Lineagen, Inc., Dr. Prescott was previously the Executive Director of the Huntsman Cancer Institute, where he held the prestigious H.A. & Edna Benning Presidential Endowed Chair.

Dr. Prescott was appointed by former Secretary of Health and Human Services, Michael O. Leavitt, to the National Advisory Council for Human Genome Research, which advises the Department of Health and Human Services (DHHS), the National Institutes of Health (NIH), and the National Human Genome Research Institute (NHGRI). 

Dr. Prescott earned a B.S. from Texas A&M and his M.D. from the Baylor College of Medicine.

With almost 30 years experience in the biotechnology and biomedical industries, Mr. Middleton currently has active roles as Chairman, CEO, or Director of Sanderling portfolio companies, including Stereotaxis (NASDAQ: STXS), Favrille (NASDAQ: FVRL), CardioNet, Novocell, Cylene, Endocyte and Actimis.

Mr. Middleton was a co-founder of Genentech, where he served as VP of Finance, Administration, Corporate Development, and CFO. He also served as President of Genentech Development Corporation. During his time at Genentech, he concluded more than $200 million in partnering and institutional funding, including Genentech's IPO, a first-ever in the biotechnology industry. Mr. Middleton founded Morgan Stanley Ventures in 1984.

Mr. Middleton earned a B.S. in chemistry from MIT and an MBA with distinction from Harvard Business School.

Mary Tanner is Senior Managing Director of EVOLUTION Life Sciences Partners (ELSP). She is also co-founder and Managing Partner of Life Sciences Partners, LLC, a financial advisory firm.  At Life Sciences Partners, Ms. Tanner specializes in healthcare investment and strategic advisory work.  Before joining ELSP, Ms. Tanner was Senior Managing Director of both Burrill & Company and Burrill Securities. She is a former Senior Managing Director at Lehman Brothers, Bear Stearns and Peter. J. Solomon Company. 

At Lehman Brothers, with Frederick Frank, she headed a global healthcare investment banking franchise for over twenty years. Ms. Tanner has devoted more than 25 years to the global healthcare and biotechnology industry. Her expertise includes the ethical pharmaceutical industry, biotechnology, diagnostics, medical devices, healthcare services, cosmetics and consumer medicines, as well as green technologies in chemicals.

In addition to her well-known work with large companies, she specializes in domestic and cross-border transactions between large and small companies, including corporate partnering and minority investments and cross-border mergers. Ms. Tanner has directed over 500 mergers and acquisitions, over 130 initial public offerings and hundreds of financings. Ms. Tanner's clients have included Pfizer in its $60 billion acquisition of Pharmacia, Amgen in its $16 billion acquisition of Immunex, Rhône-Poulenc in its acquisition of Rorer, followed by representing Rhône-Poulenc Rorer in its acquisition of U.K. company Fisons, and BASF/BASF Pharma, in its acquisition of U.K. Boots Pharmaceuticals.

Ms. Tanner received a B.A. magna cum laude from Harvard University. Ms. Tanner is a member of the Board of Directors of Lineagen, Inc., a molecular diagnostic company, and Genticel , S.A., an immuno oncology company.  She serves on the Dean's Council of the Yale Medical School and the Yale School of Organization and Management Advisory Board. Ms. Tanner has been honored for her contributions to biotechnology with numerous awards, including the highest award of Springboard Enterprises, the Oracle, for professional accomplishment and mentoring of women entrepreneurs.

Mr. Walsh has served as a Director since June, 2014.  Mr. Walsh was most recently Executive Vice President, Chief Commercial Officer at Cypress Bioscience, Inc.  In this capacity, Mr. Walsh led the creation of a 115-person sales force and established commercial operations to support the launch of Savella (milnacipran), a pharmaceutical product for fibromyalgia, through a partnership with Forest Laboratories, Inc. as well as personalized medicine services focused in rheumatology.

Prior to Cypress, Mr. Walsh was the founder, Chairman and CEO of Proprius Pharmaceuticals, Inc., a specialty pharmaceutical and personalized medicine company focused in rheumatology and pain management, which was acquired by Cypress in 2008. Prior to Proprius, Mr. Walsh was co-founder and Executive Chairman at Prometheus Laboratories, where he also held the positions of President, Chief Operating Officer and Chief Executive Officer, from the founding of the company through late 2004. He is largely responsible for developing the company's unique strategy and business model, as well as leading its development into a profitable, integrated specialty pharmaceutical and clinical diagnostics company focused in gastroenterology. 

Prior to Prometheus, Mr. Walsh was with Quidel Corporation in a number of senior executive roles, including Director of Worldwide Marketing and Business Development, and Director of European Operations.  Prior to Quidel, he was Manager of Therapeutic Operations for La Jolla Pharmaceutical Company. 

Mr. Walsh has a Bachelor of Science degree from the University of Notre Dame and an M.B.A. from Pepperdine University.

David Fitzgerald has broad experience in both private equity and mergers and acquisitions. Mr. Fitzgerald's primary focus has been on the healthcare, information technology and business services sectors. Prior to joining Petra, Mr. Fitzgerald was a General Partner at Richland Ventures, a venture capital fund with $340 million in assets under management. Earlier in his career, Mr. Fitzgerald led market development and acquisition activities for InformDx, a diagnostic laboratory company and THG Management Services, a managed healthcare company.

Mr. Fitzgerald has board-level experience with many successful growth companies including: SpecialtyCare (sold to American Securities), US Healthworks (sold to Dignity Health), Televox (sold to West Corp.), Appriss (sold to Bain Capital), Synhrgy (sold to Mercer), Nuvox Communications (sold to Windstream), Salveo Specialty Pharmacy (sold to Catamaran). He currently serves as a director on the boards of Urgent Team, New Century Hospice, Opportune IT Healthcare Solutions, Access Media 3, SUN Behavioral Health, Clinipace Worldwide, VirMedica and Lineagen.

Mr. Fitzgerald received a B.A. degree from Washington & Lee University.